Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia

Karen Phaik-Har Lim, MS, Tricia L Peters, MD, MS, Marie-Luise Berres, MD, Jeremy Price, Hitoshi Takizawa, PhD, Philip Lupo, PhD, M. John Hicks, MD, PhD, DDS, Albert Shih, Stephen James Simko, III, MD, Kenneth Matthew Heym, MD, Venetia Bigley, MD, PhD, Matthew P. Collin, MD, PhD, Markus G. Manz, MD, Kenneth McClain, MD, PhD, Miriam Merad, MD, PhD, Carl E. Allen, MD, PhD

Blood (2013) 122 (21): 103.

https://doi.org/10.1182/blood.V122.21.103.103

Published: 2013

Journal Articles

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

Kile Green, BSc(Hons), Rob Sellar, MD, Laura Jardine, MD, Janice Ward, Paul Ferguson, MD, Pip Nicolson, MD, Kim Pearce, PhD, Venetia Bigley, MD, PhD, Graham Jackson, MD, Sandeep Nagra, MD, Anne M Dickinson, PhD, Kirsty Thomson, MD, Stephen Mackinnon, MD, Charles Craddock, MD, Matthew P. Collin, MD, PhD, Karl S Peggs, MD

Blood (2013) 122 (21): 4540.

https://doi.org/10.1182/blood.V122.21.4540.4540

Published: 2013

Journal Articles

The Equilibration of Peripheral Blood and Tissue CD3+ T Cell Engraftment Is Influenced by Graft Versus Host Disease Following Reduced Intensity Conditioning Stem Cell Transplantation

Victoria Harries, Rachel Dickinson, PhD, Venetia Bigley, MD, Matthew Collin, MD, PhD

Blood (2010) 116 (21): 2546.

https://doi.org/10.1182/blood.V116.21.2546.2546

Published: 2010

Journal Articles

Drug-Induced, NKG2D-Dependent Sensitization of ALL Cell Lines to NK Recognition.

Laura Spence, MD, Sophie Hambleton, MD, PhD, Venetia Bigley, MD, Sarah Pagan, Matthew Collin, MD, PhD

Blood (2009) 114 (22): 2024.

https://doi.org/10.1182/blood.V114.22.2024.2024

Published: 2009

Journal Articles

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Andrew Charlton, MD, Laura Spence, MD, Venetia Bigley, MD, Natasha Groves, PhD, Geoff Hale, PhD, Sarah Pagan, BSc, Brie E Turner, PhD, Gail Jones, MD, PhD, Graham H Jackson, MD, PhD, Anne M Dickinson, PhD, Matthew Collin, MD, PhD

Blood (2009) 114 (22): 3333.

https://doi.org/10.1182/blood.V114.22.3333.3333

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

The Equilibration of Peripheral Blood and Tissue CD3+ T Cell Engraftment Is Influenced by Graft Versus Host Disease Following Reduced Intensity Conditioning Stem Cell Transplantation

Drug-Induced, NKG2D-Dependent Sensitization of ALL Cell Lines to NK Recognition.

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

The Equilibration of Peripheral Blood and Tissue CD3+ T Cell Engraftment Is Influenced by Graft Versus Host Disease Following Reduced Intensity Conditioning Stem Cell Transplantation

Drug-Induced, NKG2D-Dependent Sensitization of ALL Cell Lines to NK Recognition.

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only